Navigation Links
Alexza Reports 2010 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update
Date:3/15/2011

MOUNTAIN VIEW, Calif., March 15, 2011 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) reported today financial results for the fiscal quarter and year ended December 31, 2010, and provided a general corporate update.  Alexza recorded net income of $25.4 million in the fourth quarter of 2010, while posting a net loss of $1.5 million for the year ended December 31, 2010, as reported in accordance with accounting principles generally accepted in the United States (GAAP), compared to a net loss of $19.8 million and $56.1 million in the quarter and year ended December 31, 2009, respectively.  At December 31, 2010, Alexza had consolidated cash, cash equivalents and marketable securities of $41.4 million.

"All of Alexza has worked very hard over the past months to address the issues raised in the AZ-004 Complete Response Letter," said Thomas B. King, President and CEO of Alexza.  "Based on our End-of-Review meeting with the FDA, ongoing internal work and work with external consultants and advisors, we believe all of the issues raised in the CRL are resolvable.  We remain on track with our plan to resubmit the AZ-004 NDA in July 2011."

Alexza Corporate Update

The following key events occurred since the beginning of the fourth quarter of 2010:

  • Alexza received a Complete Response Letter (CRL) from the U. S. Food and Drug Administration (FDA) to Alexza's New Drug Application (NDA) for AZ-004 Staccato loxapine on October 8, 2010.
  • Alexza reacquired the U.S. and Canadian rights for AZ-004 from Biovail Laboratories International SRL (BLS), now a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc.  All AZ-004 rights reverted to Alexza, effective January 16, 2011.
  • Alexza completed an End-of-Review meeting with the FDA for the AZ-004 NDA in December 2010, and received the FDA minutes from the
    '/>"/>

  • SOURCE Alexza Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Alexza to Announce 2010 Year-End Financial Results on Tuesday, March 15, 2011
    2. Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA
    3. Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato® Loxapine)
    4. Alexza Pharmaceuticals Reports 2010 Third Quarter Financial Results and Provides Business Update
    5. Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010
    6. Alexza Pharmaceuticals Reacquires U.S. and Canadian Rights for AZ-004 (Staccato® Loxapine)
    7. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
    8. Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA
    9. Alexzas Staccato® Nicotine Licensed to Cypress Bioscience
    10. Alexza Pharmaceuticals to Present at Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference
    11. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
    (Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
    (Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
    Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
    ... 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) today reported ... Arena reported a lower net loss allocable to common stockholders in ... share, compared to a net loss allocable to common stockholders in ... share, and a net loss allocable to common stockholders in the ...
    ... TessArae® LLC, a global leader in resequencing microarray-based ... solutions for genetic testing of the mutations that ... TessArae,s expertise in microarray-based resequencing with novel nucleotide ... for all targeted mutations in multiple genes of ...
    Cached Medicine Technology:Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 2Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 3Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 4Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 6Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 7Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 8Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 9TessArae Delivers Lower Cost Option to Genetic Testing Market 2
    (Date:4/24/2014)... me out to the ballgame, doesn,t exactly conjure up ... likely culprits include French fries, soda and the occasional ... play youth baseball, eating unhealthy food during practices and ... researchers at Wake Forest Baptist Medical Center. The study, ... Obesity , found that high-calorie snacks and sugar-sweetened drinks ...
    (Date:4/24/2014)... the new Institute for Biomedical Sciences at Georgia ... federal grant to develop novel therapeutics against Respiratory ... the Eunice Kennedy Shriver National Institute Of Child ... of Health will support Plemper,s drug development goals ... one distinct alternative compound. , Infections by RSV, ...
    (Date:4/24/2014)... prescription opioid overdose deaths was outlined yesterday in the ... of agencies in the U.S. Department of Health and ... providers to expand their use of medications to treat ... number of misperceptions that have limited access to these ... can be used in combination with behavior therapies to ...
    (Date:4/24/2014)... the first in the world to discover a gene ... jaw. , Ameloblastoma is an odontogenic tumour with a ... often found in the posterior of the lower jaw. ... deficiencies in the jaws as well as loss of ... need for surgery and the recurrence of ameloblastoma, but ...
    (Date:4/24/2014)... The National Science Foundation has awarded LSU Health ... Undergraduates (REU) Site grant in the amount of ... undergraduates from diverse social and educational backgrounds, underrepresented ... area. The project will provide students with ... 2014-16. It will be led by Principal ...
    Breaking Medicine News(10 mins):Health News:Take the bat, leave the candy 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4
    ... a healthy diet appears to lower blood pressure in ... in women with high blood pressure, according to a ... ,The American Heart Association estimates that high ... 1 billion individuals worldwide. The most common-and deadly-result is ...
    ... here allegedly committed suicide Tuesday morning , with police attributing ... of the orthopaedics department, was found dead at around 7.00 ... south Delhi. ,Sharma, who is said to have ... around 6.00 a.m. to monitor his patients. After 20 minutes ...
    ... a super sleuth of potentially deadly prescription drug reactions. ... RADAR (Research on Adverse Drug Events and Reports) ... swoop in to investigate early signs of trouble years ... ,A new study by Bennett, the A.C. ...
    ... recently examined how researchers in Tanzania are training rats ... researchers' efforts "capitalize" on the rats' strong sense of ... ,Bart Weetjens, a former industrial designer, developed the idea ... land mines, after he visited minefields and saw German ...
    ... may be the disease generally identified with the third ... its tentacles everywhere. US authorities fear that an American ... flights this month to the potentially lethal disease. The ... authorities are looking for travelers who were aboard Air ...
    ... accumulating that depression is a risk factor for osteoporosis, ... Watch. A recent study found that people ages ... serotonin reuptake inhibitors (SSRIs) had double the rate of ... points to depression itself as a source of endocrine ...
    Cached Medicine News:Health News:Soy Nuts may Improve Blood Pressure, Cholesterol Levels in Women 2Health News:Researchers Found Drug Effects of Deadly Prescription Well Before FDA 2Health News:Researchers Found Drug Effects of Deadly Prescription Well Before FDA 3Health News:Researchers Training Rats To Diagnose TB 2Health News:American Who Exposed Air Passengers to Drug Resistant TB Quarantined 2Health News:American Who Exposed Air Passengers to Drug Resistant TB Quarantined 3
    These simple but effective single-dose, hands-off, ampulized applicators have revolutionized skin preparation in hospitals....
    ... Anti-HTLV Mixed Titer Performance Panel consists of ... to strong positive for antibodies to HTLV ... for use by manufacturers and diagnostic laboratories ... data from all major test systems are ...
    Comprised of a monofilament polypropylene mesh coated with hydrophilic porcine collagen, Pelvitex™ mesh is clinically proven coating to enhance the healing process, along with the strength and d...
    The Repliform Tissue Regeneration Matrix is an acellular human dermal allograft that when surgically implanted is intended to function as a template, facilitating the body's fibroblasts to regenerate...
    Medicine Products: